Here are five things to know:
1. The selective oral Janus kinase inhibitor was approved in 2012 for rheumatoid arthritis and in 2017 for psoriatic arthritis.
2. Tofacitinib is the first oral medication approved for long-term use in ulcerative colitis; other FDA-approved long-term treatments must be delivered through intravenous infusion or subcutaneous injection.
3. Two eight-week placebo-controlled trials demonstrated that 10 milligrams of tofacitinib given twice daily induces remission in 17 to 18 percent of patients by week eight.
4. A placebo-controlled trial involving patients who achieved a clinical response by eight weeks and were given at a dose of 5 or 10 milligrams twice daily induced remission by 52 weeks in 34 and 41 percent of patients, respectively.
5. The FDA does not recommend tofacitinib be used in combination with biological therapies for ulcerative colitis or with potent immunosuppressants such as azathioprine and cyclosporine.
More articles on gastroenterology:
3 insights into Fujifilm’s soon-to-debut endoscope
Marshall Health, Kansas City VA Medical Center & more: 3 GI practices in the news
Dr. Marc Subik returns to Marshall Health — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
